What is Caldera Therapeutics?
Caldera Therapeutics is a specialized clinical-stage biotechnology firm dedicated to the development of CLD-423, a first-in-class bispecific antibody. The company focuses on targeting the clinically validated IL-23p19 and TL1A pathways, which are central to the pathology of inflammatory bowel disease (IBD) and various other immunologic conditions. By leveraging a senior leadership team with extensive experience in therapeutic discovery, Caldera Therapeutics aims to address significant unmet medical needs through precision medicine. The company's market position is bolstered by a robust intellectual property strategy and a clear roadmap for clinical validation, distinguishing it as a high-potential player in the immunology sector.
How much funding has Caldera Therapeutics raised?
Caldera Therapeutics has raised a total of $112.5M across 2 funding rounds:
Other Financing Round
$37.5M
Series A
$75M
Other Financing Round (2026): $37.5M with participation from Janus Henderson Investors, Omega Alpha Spac, and Wellington Management
Series A (2026): $75M led by venBio Partners and Atlas Venture
Key Investors in Caldera Therapeutics
Atlas Venture
A pioneering early-stage venture capital firm focused on building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
venBio Partners
A life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs.
Wellington Management
A global, independent investment management firm providing institutional clients with portfolio management, research, and tailored investment solutions across various asset classes.
What's next for Caldera Therapeutics?
With the recent capital injection, Caldera Therapeutics is poised to prioritize the advancement of its clinical trials and the expansion of its research capabilities. The strategic focus will likely remain on the successful progression of CLD-423, ensuring that the company meets key regulatory and clinical milestones. Furthermore, the firm is expected to leverage its strong investor network to explore potential partnerships or future financing opportunities that could facilitate long-term commercialization. As the biotech industry continues to prioritize novel inflammatory treatments, Caldera's ability to execute on its development timeline will be the primary driver of its future valuation and market impact.
See full Caldera Therapeutics company page
